Integrity Advisory’s AbbVie ABBV Stock Holding History

Integrity Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$296K	Sell	1,830 -23	-1%	-$3.53K	0.27%	60
2022 Q3	$249K	Buy	1,853 +29	+2%	+$4.16K	0.23%	63
2022 Q2	$279K	Sell	1,824 -95	-5%	-$14.5K	0.27%	56
2022 Q1	$311K	Buy	+1,919	New	+$279K	0.31%	58

Other funds holding ABBV

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Integrity Advisory's ABBV Position: Q4 2022 in Review

Integrity Advisory reduced its AbbVie (ABBV) stake by 1.2% in Q4 2022, selling an estimated $3.53K and leaving 1,830 shares worth $296K. The position accounts for 0.27% of the portfolio, ranked #60.

Integrity Advisory first reported a position in ABBV in Q1 2022 and has held it in 4 quarters since. The position peaked at $311K in Q1 2022. 3,167 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

Integrity Advisory held 1,830 shares of AbbVie worth $296K as of Q4 2022.
Integrity Advisory sold 23 AbbVie shares in Q4 2022, an estimated $3.53K.
AbbVie made up 0.27% of Integrity Advisory's portfolio in Q4 2022, its #60 holding.
Integrity Advisory first reported a position in AbbVie in Q1 2022 and has held it in 4 quarters since.
Integrity Advisory's AbbVie position peaked at $311K in Q1 2022.
3,167 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Integrity Advisory's 13F filing for Q4 2022, filed 24 Jan 2023.